SELLAS Life Sciences Group, Inc.
Complete enrollment for the REGAL study
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 6 Apr 2022
- Due
- 31 Mar 2023
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“enrollment for the regal study will be completed by the end of this year, or early in the first quarter of 2023”
What we found
Evidence strength A What the grades mean
The company did not complete enrollment for the REGAL study by the first quarter of 2023; subsequent filings indicate enrollment was still ongoing in late 2023.
-
A SELLAS Life Sciences Group, Inc. 10-Q filed 2023-11-09
“We expect to complete enrollment in the REGAL study, other than the approximately 20 to 25 patients anticipated to be enrolled in China, in November 2023.” ✓ confirmed on the page
Market reaction: the shares moved -7.1% against the S&P 500 over the three sessions around the disclosure (8 Nov 2023 to 13 Nov 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +244 days
- Language weakened: firm → expected
- 4 versions
-
Version 1 · original · stated 6 Apr 2022
Deadline 31 Mar 2023 (“early in the first quarter of 2023”) · wording firm
-
Version 2 · stated 12 May 2022
Deadline 31 Mar 2023 (“early in the first quarter of 2023”) · wording expected
“The Company believes that enrollment for the REGAL study will be completed in late 2022 or early in the first quarter of 2023”
-
Version 3 · stated 10 Aug 2023
Deadline 31 Dec 2023 (“second half of this year”) · wording expected
“We expect to complete enrollment in our Phase 3 REGAL study of galinpepimut-S (GPS) in the second half of this year.”
-
Version 4 · stated 13 Oct 2023
Deadline 30 Nov 2023 (“in November 2023”) · wording expected
“The Company expects to complete enrollment in the REGAL study, other than the 20-25 patients anticipated to be enrolled in China, in November 2023.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Enrollment for the REGAL study
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-SLS-001989 · Corrections policy